A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling Journal Article

Authors: McArthur, H. L.; Diab, A.; Page, D. B.; Yuan, J.; Solomon, S. B.; Sacchini, V.; Comstock, C.; Durack, J. C.; Maybody, M.; Sung, J.; Ginsberg, A.; Wong, P.; Barlas, A.; Dong, Z.; Zhao, C.; Blum, B.; Patil, S.; Neville, D.; Comen, E. A.; Morris, E. A.; Kotin, A.; Brogi, E.; Wen, Y. H.; Morrow, M.; Lacouture, M. E.; Sharma, P.; Allison, J. P.; Hudis, C. A.; Wolchok, J. D.; Norton, L.
Article Title: A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling
Abstract: Purpose: To assess the safety and tolerability of preoperative cryoablation-mediated tumor antigen presentation and/or ipilimumab- mediated immune modulation in women with operable breast cancer. Experimental Design: In this pilot study, 19 women with breast cancer for whom mastectomy was planned were treated with preoperative tumor cryoablation (n = 7), single-dose ipilimumab at 10 mg/kg (n = 6), or both (n = 6). The primary outcome for this pilot study was safety/tolerability as defined as freedom from delays in pre-planned, curative-intent mastectomy. Exploratory studies of immune activationwere performed on peripheral blood and tumor. Results: Preoperative cryoablation and/or ipilimumab were safe and tolerable, with no delays in pre-planned surgery. Grade III toxicity was seen in 1 of 19 (unrelated rash after ipilimumab). Combination therapy was associated with sustained peripheral elevations in: Th1-type cytokines, activated (ICOS+) and proliferating (Ki67+) CD4+ and CD8+ T cells, and posttreatment proliferative T-effector cells relative to T-regulatory cells within tumor. Conclusions: Preoperative cryoablation and single-dose ipilimumab are safe alone or in combination with no surgical delays incurred. Potentially favorable intratumoral and systemic immunologic effects were observed with the combination, suggesting the possibility for induced and synergistic antitumor immunity with this strategy. © 2016 American Association for Cancer Research.
Journal Title: Clinical Cancer Research
Volume: 22
Issue: 23
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2016-12-01
Start Page: 5729
End Page: 5737
Language: English
DOI: 10.1158/1078-0432.ccr-16-0190
PROVIDER: scopus
PMCID: PMC5161031
PUBMED: 27566765
Notes: Article -- Export Date: 3 January 2017 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Sujata Patil
    383 Patil
  2. Monica Morrow
    439 Morrow
  3. Janice Sinae Sung
    33 Sung
  4. Mario E Lacouture
    261 Lacouture
  5. Clifford Hudis
    840 Hudis
  6. Larry Norton
    563 Norton
  7. Alan L Kotin
    10 Kotin
  8. Jedd D Wolchok
    656 Wolchok
  9. Elizabeth A Morris
    243 Morris
  10. Phillip Wong
    37 Wong
  11. Majid Maybody
    72 Maybody
  12. Elizabeth Comen
    47 Comen
  13. Yong Hannah Wen
    118 Wen
  14. Stephen Solomon
    266 Solomon
  15. Afsar Barlas
    21 Barlas
  16. Edi Brogi
    304 Brogi
  17. Jianda Yuan
    100 Yuan
  18. Deirdre Neville
    11 Neville
  19. Zhiwan Dong
    8 Dong
  20. David B Page
    28 Page
  21. Brian Philip Blum
    11 Blum
  22. Jeremy Charles Durack
    84 Durack
  23. Chunjun   Zhao
    3 Zhao